secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2022-03-09T23:59:59+00:00
Accession:  0001178913-22-001006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab reports FY2021 net loss of $12.5M; revises CM-101 clinical program to extend cash runway through end 2023
--------------------------------------------------------------------------------

- Net loss $12.5M ($0.06 per share) in FY2021 vs $6.0M in FY2020; cash $61.2M at Dec 31, 2021.
- Expanding Phase 2 PSC trial with dose-finding cohorts and open-label extension; interim analysis expected H2 2022.
- Focusing SSc trial on earlier proof of concept; trial initiation anticipated H2 2022.
- Winding down liver fibrosis subcutaneous formulation study; data readout targeted near end of 2022.
- Cash runway extended ~6 months to end of 2023; company expects 3-4 data readouts over next 24 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322001006/0001178913-22-001006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322001006/zk2227450.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-001006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer